Orca Bio has raised a total of $192 million through multiple funding rounds, with its most recent $192 million Series D in June 2020 led by Lightspeed Venture Partners. The late-stage biotechnology company focuses on high-precision allogeneic cell therapies for cancer and autoimmune diseases, leveraging regulatory T cells to improve patient outcomes with fewer risks.
Keep reading to explore Orca Bio's funding journey, key investors, and what's next for this pioneering biotechnology company.
What Is Orca Bio and What Does It Do?
Orca Bio is a late-stage biotechnology company dedicated to developing high-precision cell therapies for cancer and autoimmune diseases. Their investigational allogeneic T-cell immunotherapies harness regulatory T cells to deliver better outcomes with fewer risks.
Driven by a mission to expand the life-changing benefits of cell therapy, Orca Bio focuses on advancing treatments without compromise, aiming to transform the treatment of blood cancers, autoimmune diseases, and genetic disorders through innovative therapeutic approaches.
How Much Funding Has Orca Bio Raised?
- Series D
- Amount Raised: $192M
- Date: June 2020
- Lead Investors: Lightspeed Venture Partners
- Motivation: Develop Orca Bio's pipeline of cell therapies and manufacturing technology
Total Funding Raised: $192M
Latest Funding Date: June 2020
Key Investors
- Lightspeed Venture Partners
- Details: Venture capital firm focusing on early-stage investments in technology
- Investment Focus Areas: Technology, enterprise, consumer, and health sectors
- Notable Investments: Snapchat, GrubHub, Affirm
- 8VC
- Details: Venture capital firm investing in technology and healthcare companies
- Investment Focus Areas: Technology, healthcare, logistics, financial services
- Notable Investments: Palantir, Wish, Guardant Health
- DCVC Bio
- Details: Venture capital firm specializing in deep tech and life sciences
- Investment Focus Areas: Biotechnology, life sciences, healthcare
- Notable Investments: Zymergen, Recursion Pharmaceuticals, Pivot Bio
- Mubadala Investment Company
- Details: Global investment firm based in Abu Dhabi, managing a diverse portfolio
- Investment Focus Areas: Technology, healthcare, infrastructure
- Notable Investments: SoftBank Vision Fund, Cologix, Medallia
- Kaiser Foundation Hospitals
- Details: Part of the Kaiser Permanente healthcare system
- Investment Focus Areas: Healthcare services, infrastructure
Where Is Orca Bio's Headquarters?
Orca Bio is headquartered in the United States (exact location not publicly disclosed), providing access to advanced biotechnology research, clinical trial resources, and strategic partnerships in the life sciences ecosystem.
What's Next for Orca Bio?
Orca Bio is poised to revolutionize treatments for blood cancers, autoimmune diseases, and genetic disorders through its high-precision allogeneic cell therapies, including TRGFT-201 and OGFT-001, which aim to replace conventional bone marrow transplants with reduced complications.
Future opportunities include advancing clinical trials, refining manufacturing platforms, and attracting further investments for expansion into new therapeutic areas and markets. Challenges include regulatory hurdles, high development costs, and competition from other biotech firms; however, strong investor backing and innovative therapies position Orca Bio for a long-term impact in cell therapy.
Get Investor & Funding Insights with TexAu
TexAu provides detailed fundraising information on companies like Orca Bio. Track investors, monitor funding rounds, and gather actionable insights to strengthen your sales and business strategy.
Sign up for free on TexAu and turn data into smarter, faster business decisions.
